Free Trial

Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume - Here's What Happened

Oculis logo with Medical background

Oculis Holding AG (NASDAQ:OCS - Get Free Report) shares saw strong trading volume on Friday . 14,134 shares were traded during trading, a decline of 61% from the previous session's volume of 36,600 shares.The stock last traded at $17.52 and had previously closed at $16.58.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $30.00 target price on shares of Oculis in a research note on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $29.20.

Get Our Latest Stock Analysis on OCS

Oculis Trading Up 3.0 %

The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The company's 50 day moving average price is $15.72 and its 200 day moving average price is $13.18. The company has a market cap of $692.15 million, a price-to-earnings ratio of -8.85 and a beta of -0.34.

About Oculis

(Get Free Report)

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

Recommended Stories

Should you invest $1,000 in Oculis right now?

Before you consider Oculis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.

While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?
SoundHound Stock Explodes Again – Is a Major Breakout Coming?
How Fintech Strategy at FinWise Bancorp and CEO Vision Are Driving 78% Gains

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines